CICERO-trial
Objective:
To assess whether intracoronary (ic) bolus
injection of abciximab improves myocardial
perfusion compared to intravenous (iv) bolus
injection in STEMI patients undergoing
primary PCI with thrombus aspiration.
Study:
Single center, single blind, randomized trial.
Population: Patients ≥ 18 year with STEMI < 12 hours.
No shock.
Endpoint: Complete ST-T resolution (> 70%).
CICERO-trial
Abciximab
0.25 mg/kg ic
N=271
Patients enrolled
N=534
Abciximab
0.25 mg/kg iv
N=263
Thrombectomy
PCI
CICERO-trial
ST-T resolution
100
80
60
40
20
0
>70%
<30%
10
26
64
IC
Myocardial blush grade
3
30-70%
10
28
62
IV
100
80
60
40
p=0.844 20
0
2
24
34
42
34
34
33
IC
IV
0/1
p=0.052
CICERO-trial
IC n=126
4
2
0
2,92
1,17
IV n=122
3,31
1,71
p=0.006
p=0.032
AUC CK-MB x
100
AUC troponin T
CICERO-trial
Conclusion: In STEMI patients undergoing primary PCI
with thrombus aspiration, an ic bolus injection
of abciximab does not improve myocardial
reperfusion as assessed by ST-segment
resolution. Enzymatic infarct size was smaller
in the intracoronary abciximab group.
Gu et al. Circulation 2010;21;122(25):2709-11